Celldex Therapeutics, Inc. announced additions to the Board of Directors and senior management team. Keith L. Brownlie was elected to the Company's Board of Directors at Celldex's 2017 Annual Meeting of Stockholders held June 15, 2017. Sam Martin has been promoted to Senior Vice President and Chief Financial Officer, effective July 1, 2017.

Mr. Martin joined Celldex in April 2009 and currently serves as Vice President, Finance. Mr. Martin will assume the responsibilities of Avery “Chip” Catlin, who is retiring on June 30, 2017. Sarah Cavanaugh has been promoted to Senior Vice President, Corporate Affairs and Administration.

Ms. Cavanaugh joined Celldex in August 2012 as Vice President of Investor Relations and Corporate Communications. She will continue fulfilling those responsibilities and will assume leadership for human resources, employee relations, organizational development and internal communications. Brownlie retired from Ernst & Young in 2010.

He currently serves as a member of the boards of directors and chairman of the audit committees for two publicly-held biopharmaceutical companies—Soligenix, Inc. and RXi Pharmaceuticals Corporation, and he previously served in the same capacity for the publicly-held EpiCept Corporation and Cancer Genetics, Inc. Prior to joining Celldex, Mr. Martin served as the Director of Finance and Corporate Compliance for Alseres Pharmaceuticals, Inc. Prior to joining Celldex, Ms. Cavanaugh served from 2007 to 2012 as a Vice President at MacDougall Biomedical Communications.